As those of you familiar with us know, AgelessRx is fully committed to the invaluable role research plays in medicine and the limitless opportunities it presents for the future.
In that spirit, AgelessRx is proud to play a leading role in discovering new, scientifically-proven treatment options that prevent age-related diseases and reverse age-related damage. Below, you can find a quick update on our two ongoing research projects, PEARL and Post-COVID.
Quick PEARL Update
The Participatory Evaluation of Aging with Rapamycin for Longevity (PEARL) Trial has been a focal point for our research efforts. After successfully closing a crowdfunding campaign, raising over $180,000, we’re in the active recruiting and enrolling phase of the project. Our aim is to establish a long-term safety profile, determine the long-term efficacy of Rapamycin in reducing clinical aging measures, and biochemical and physiological endpoints associated with declining health and aging in healthy older adults.
The official PEARL protocol can be found on the U.S. National Library of Medicine’s Clinical Trials webpage here.
What’s next? We’re excited to announce that we’ve begun onboarding PEARL participants and will continue recruiting on a rolling basis. If you’re interested in learning more on how you may qualify for PEARL, check out eligibility requirements and additional information here.
Quick Post-COVID Update
Our Pilot Study Into LDN and NAD+ for Treatment of patients with Post-COVID-19 Syndrome, found on the U.S. National Library of Medicine’s Clinical Trials (here), is intended to study the reduction of fatigue and improvement of quality of life in individuals with Post-COVID-19 syndrome using combined treatment of LDN and NAD+.
What’s the latest? We’ve recently converted this away from a double-blinded, placebo controlled study to an observational study and have opened up inclusion criteria.
We are still actively accepting new participants. If you’re interested in learning more, or know someone else who may be interested, check out our eligibility criteria and find more information here.
More to come in the near future! To our donors, staff, participants, and lab partners, among many others, we appreciate all of your continued support. We can’t wait to share the results.
For more information on AgelessRx Research, click here.